Back to top
more

Verrica Pharmaceuticals (VRCA)

(Real Time Quote from BATS)

$7.08 USD

7.08
32,041

+0.16 (2.31%)

Updated Apr 16, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VRCA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Verrica Pharmaceuticals Inc. [VRCA]

Reports for Purchase

Showing records 1 - 20 ( 32 total )

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 1

03/01/2024

Company Report

Pages: 7

4Q23: YCANTH Beats in First Full Quarter; We Raise Year-One Sales, Margins, and Our Target to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 2

11/20/2023

Company Report

Pages: 6

3Q23: Solid YCANTH Early Launch Indicators; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 3

10/12/2023

Company Report

Pages: 6

KOLs Bolster View on Strong YCANTH Prospects; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 4

07/27/2023

Company Report

Pages: 6

Post-Approval Pullback Overdone; YCANTH Should Be Differentiated Derm Launch; Reiterate Buy; Raise Target to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 5

07/17/2023

Company Report

Pages: 6

Expect Final Approval, Finally, End of This Week; Launch by September; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 6

01/25/2023

Company Report

Pages: 6

VP-102 NDA Resubmitted; Expect Approval by July; Reiterate But

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 7

11/14/2022

Company Report

Pages: 6

3Q22: VP-102 On Track for 1Q23 NDA Resubmission; Could Put Launch Slightly Ahead of Our Projections; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 8

08/12/2022

Company Report

Pages: 6

2Q22: Moving Quickly With Alternate Supplier to Potentially File VP-102 in 1Q23; Tweak PT to $11 Post Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 9

06/29/2022

Company Report

Pages: 5

FDA Meeting Suggests Potential Expedited NDA Resubmission With Alternate API Manufacturer

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 10

05/31/2022

Company Report

Pages: 7

Third Party Quality Issues Strike Again; Still See Ultimate Approval and Potential But Push Out 18 Mths; PT Down to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 11

03/07/2022

Company Report

Pages: 7

VP-102 Homestretch (Hopefully) With May 24 PDUFA Date; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 12

11/30/2021

Company Report

Pages: 4

VP-102 NDA Resubmitted; If Qualifies as Class I Review, Potential January 24 PDUFA Date; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 13

11/15/2021

Company Report

Pages: 7

Supplier VAI Status Hopefully Clears Way for VP-102 Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 14

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for VRCA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 15

09/22/2021

Company Report

Pages: 6

Supplier 483s Trigger Surprise CRL; Management Aims for Expedited Resolution

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 16

06/01/2021

Company Report

Pages: 7

PDUFA Push to September Doesn’t Dampen Our Approval Confidence; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 17

05/19/2021

Company Report

Pages: 9

Expect June 23 VP-102 Molluscum Approval and Late-Summer Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 18

03/08/2021

Company Report

Pages: 9

June PDUFA Nearing; Japan Partner Opt-In is Encouraging Read-Through

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 19

12/24/2020

Company Report

Pages: 7

YCANTH NDA Resubmitted Ahead of Schedule; We See High Probability of Mid-21 Approval; Reiterate Buy and Raise to $21

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Verrica Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 20

11/11/2020

Company Report

Pages: 9

Positive Genital Warts Phase 2 Raises VP-102’s Therapeutic Potential Assuming YCANTH Gets Through FDA; 1Q21 Resubmission

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party